Boston Life Sciences, Inc. Announces Data to be Presented on Cethrin(R) for Spinal Cord Injury at the 2007 American Association
12 Avril 2007 - 10:22PM
PR Newswire (US)
HOPKINTON, Mass., April 12 /PRNewswire-FirstCall/ -- Boston Life
Sciences (NASDAQ:BLSI), a biopharmaceutical company focused on the
research and clinical development of diagnostic and therapeutic
products for central nervous system (CNS) disorders, announces the
presentation of 6-month Phase I/IIa clinical data for Cethrin in
Acute Spinal Cord Injury (SCI) at the American Association of
Neurological Surgeons Annual Meeting April 14-19, 2007 in
Washington, DC. The oral presentation, "Results of the Cethrin
Phase I/IIa Prospective Clinical Trial of a Rho Inhibitor for the
Treatment of Acute Spinal Cord Injury," will be presented in the
Neurotrauma and Critical Care Scientific Session on Monday, April
16, 2007 at 3:15 EDT by Michael G. Fehlings, MD, PhD, FRC, Medical
Director of the Krembil Neuroscience Center and Head of the Spinal
Program at the University Health Network of the University of
Toronto. About Cethrin Cethrin is a recombinant protein drug
intended to facilitate the re-growth of axons during the critical
period immediately after a major injury to the spinal cord.
Following an SCI, about two-thirds of patients undergo
decompression/stabilization surgery. In this surgery, Cethrin is
delivered in a single dose directly onto the injured region of the
spinal cord without the need for further invasive procedures. About
Boston Life Sciences Boston Life Sciences, Inc. (BLSI) is engaged
in the research and clinical development of diagnostic and
therapeutic products for central nervous system (CNS) disorders.
Cethrin(R), a recombinant-protein-based drug designed to promote
nerve repair after acute spinal cord injury, has reported positive
interim results in a Phase I/IIa clinical trial. ALTROPANE(R)
molecular imaging agent is in Phase III clinical trials for the
diagnosis of Parkinson's Disease (PD). The company's research and
pre-clinical CNS programs include Inosine for the treatment of
spinal cord injury and stroke, a DAT blocker for the treatment of
Parkinson's disease, and a second generation technetium-based
molecular imaging agent for PD and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's
Hospital Boston. Contact: Sharon Correia - 508-497-2360 Boston Life
Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT:
Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360, Web
site: http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Boston Life Sciences (NASDAQ:BLSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Boston Life Sciences (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Boston Life Sciences (MM)